Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Royce Global Value Trust, Inc. was a closed ended equity mutual fund launched and managed by Royce & Associates, LLC. It invests in the public equity markets across the globe. The fund spreads its investments across diversified sectors. It invests in value oriented stocks of small-cap and micro-cap companies. The fund benchmarks the performance of its portfolio against the Russell Global SC Index. Royce Global Value Trust, Inc. was formed on November 26, 1986 and is domiciled in the United States.

Royce Global Value Trust, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

NEW YORK , JULY 30, 2025 /PRNEWSWIRE/ -- A CLOSED-END FUND THAT INVESTS IN GLOBAL EQUITIES USING A DISCIPLINED VALUE APPROACH AVERAGE WEEKLY TRADING VOLUME OF APPROXIMATELY 64,166 SHARES FUND'S ADVISER HAS MORE THAN 50 YEARS OF SMALL- AND MICRO-CAP INVESTMENT EXPERIENCE CLOSING PRICES AS OF 06/30/25 NAV 14.23 MKT 12.03 AVERAGE ANNUAL TOTAL RETURN AS OF 06/30/25     NAV (%)    MKT (%) ONE-MONTH* 5.64 4.83 YEAR TO DATE* 13.39 12.20 ONE-YEAR 18.38 12.95 THREE-YEAR 14.71 13.23 FIVE-YEAR 9.95 8.25 10-YEAR 8.16 8.10 *NOT ANNUALIZED IMPORTANT PERFORMANCE AND EXPENSE INFORMATION ALL PERFORMANCE INFORMATION REFLECTS PAST PERFORMANCE, IS PRESENTED ON A TOTAL RETURN BASIS, AND REFLECTS THE REINVESTMENT OF DISTRIBUTIONS. PAST PERFORMANCE IS NO GUARANTEE OF FUTURE RESULTS.

ROYCE GLOBAL TRUST (NYSE: RGT) AS OF JUN 30, 2025

NEW YORK , APRIL 24, 2025 /PRNEWSWIRE/ -- A CLOSED-END FUND THAT INVESTS IN GLOBAL EQUITIES USING A DISCIPLINED VALUE APPROACH AVERAGE WEEKLY TRADING VOLUME OF APPROXIMATELY 94,690 SHARES FUND'S ADVISER HAS MORE THAN 50 YEARS OF SMALL- AND MICRO-CAP INVESTMENT EXPERIENCE CLOSING PRICES AS OF 03/31/25 NAV 12.30 MKT 10.50 AVERAGE ANNUAL TOTAL RETURN AS OF 03/31/25 NAV (%) MKT (%) ONE-MONTH* -2.30 -3.40 YEAR TO DATE* -1.99 -2.07 ONE-YEAR 1.76 2.55 THREE-YEAR 1.75 -0.17 FIVE-YEAR 12.38 13.30 10-YEAR 7.11 6.98 *NOT ANNUALIZED IMPORTANT PERFORMANCE AND EXPENSE INFORMATION ALL PERFORMANCE INFORMATION REFLECTS PAST PERFORMANCE, IS PRESENTED ON A TOTAL RETURN BASIS, AND REFLECTS THE REINVESTMENT OF DISTRIBUTIONS. PAST PERFORMANCE IS NO GUARANTEE OF FUTURE RESULTS.

ROYCE GLOBAL TRUST (NYSE: RGT) AS OF MAR 31, 2025

STRATEGIC EXPANSION PAIRED WITH OVER $1M IN ANNUAL COST SAVINGS FROM OPERATIONAL RESTRUCTURING PERTH, AUSTRALIA , APRIL 23, 2025 /PRNEWSWIRE/ --ARGENT BIOPHARMA LTD. (ASX: RGT) (OTCQB: RGTLF), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY SPECIALIZING IN NEUROIMMUNE THERAPIES, IS PLEASED TO ANNOUNCE ITS OFFICIAL ENTRY INTO THE GERMAN PHARMACEUTICAL MARKET WITH THE RECEIPT OF INITIAL PURCHASE ORDERS FOR CANNEPIL AND COGNICANN, FOLLOWING RECENT REGULATORY APPROVAL.

ARGENT BIOPHARMA ENTERS GERMANY - EUROPE'S LARGEST MARKET

NEW YORK , MARCH 27, 2025 /PRNEWSWIRE/ -- A CLOSED-END FUND THAT INVESTS IN GLOBAL EQUITIES USING A DISCIPLINED VALUE APPROACH AVERAGE WEEKLY TRADING VOLUME OF APPROXIMATELY 33,066 SHARES FUND'S ADVISER HAS MORE THAN 50 YEARS OF SMALL- AND MICRO-CAP INVESTMENT EXPERIENCE  CLOSING PRICES AS OF 02/28/25 NAV 12.59 MKT 10.87  AVERAGE ANNUAL TOTAL RETURN AS OF 02/28/25 NAV (%) MKT (%) ONE-MONTH* -0.79 -0.55 YEAR TO DATE* 0.32 1.38 ONE-YEAR 9.72 7.16 THREE-YEAR 3.06 1.44 FIVE-YEAR 8.28 6.86 10-YEAR 7.18 7.16 *NOT ANNUALIZED  IMPORTANT PERFORMANCE AND EXPENSE INFORMATION ALL PERFORMANCE INFORMATION REFLECTS PAST PERFORMANCE, IS PRESENTED ON A TOTAL RETURN BASIS, AND REFLECTS THE REINVESTMENT OF DISTRIBUTIONS. PAST PERFORMANCE IS NO GUARANTEE OF FUTURE RESULTS.

ROYCE GLOBAL TRUST (NYSE: RGT) AS OF FEB 28, 2025

PERTH, AUSTRALIA , MARCH 16, 2025 /PRNEWSWIRE/ -- ARGENTBIOPHARMA LTD. (ASX: RGT) (OTCQB: RGTLF), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY ADDRESSING UNMET MEDICAL NEEDS BY DEVELOPING INNOVATIVE TREATMENTS FOR CENTRAL NERVOUS SYSTEM AND IMMUNE-RELATED DISORDERS THROUGH NEURO-IMMUNE MODULATION AND ADVANCED NANO-MEDICINE TECHNOLOGY, IS PLEASED TO ANNOUNCE POSITIVE PHASE IIB CLINICAL TRIAL RESULTS FOR CIMETRA, A NOVEL ANTI-INFLAMMATORY TREATMENT.

ARGENT BIOPHARMA EXPANDS PIPELINE WITH PROMISING DRUG CIMETRA

ADVANCED WOUND CARE MARKET PROJECTED TO EXCEED $15 BILLION GLOBALLY BY 2030 PERTH, AUSTRALIA, FEB. 12, 2025 /PRNEWSWIRE/ -- ARGENT BIOPHARMA LTD. (ASX: RGT) (OTCQB: RGTLF) HAS MADE SIGNIFICANT PROGRESS IN ITS COLLABORATION WITH SINTEF TO ENHANCE ANTIMICROBIAL THERAPIES FOR CHRONIC WOUNDS AND POTENTIAL ONCOLOGIC WOUND CARE.

ARGENT BIOPHARMA LTD. UPDATES ON SINTEF COLLABORATION FOR CHRONIC WOUND MANAGEMENT

NEW YORK , JAN. 27, 2025 /PRNEWSWIRE/ -- A CLOSED-END FUND THAT INVESTS IN GLOBAL EQUITIES USING A DISCIPLINED VALUE APPROACH AVERAGE WEEKLY TRADING VOLUME OF APPROXIMATELY 72,971 SHARES FUND'S ADVISER HAS MORE THAN 50 YEARS OF SMALL- AND MICRO-CAP INVESTMENT EXPERIENCE  CLOSING PRICES AS OF 12/31/24 NAV 12.55 MKT 10.72  AVERAGE ANNUAL TOTAL RETURN AS OF 12/31/24 NAV (%) MKT (%) ONE-MONTH* -5.05 -5.03 ONE-YEAR 11.80 14.81 THREE-YEAR -1.78 -4.18 FIVE-YEAR 5.69 5.57 10-YEAR 7.40 7.21 *NOT ANNUALIZED IMPORTANT PERFORMANCE AND EXPENSE INFORMATION ALL PERFORMANCE INFORMATION REFLECTS PAST PERFORMANCE, IS PRESENTED ON A TOTAL RETURN BASIS, AND REFLECTS THE REINVESTMENT OF DISTRIBUTIONS. PAST PERFORMANCE IS NO GUARANTEE OF FUTURE RESULTS.

ROYCE GLOBAL TRUST (NYSE: RGT) AS OF DEC 31, 2024

PERTH, AUSTRALIA , JAN. 7, 2025 /PRNEWSWIRE/ -- ARGENT BIOPHARMA (ASX:RGT) (OTCQB:RGTLF),A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY ADDRESSING UNMET MEDICAL NEEDS BY DEVELOPING INNOVATIVE TREATMENTS FOR CENTRAL NERVOUS SYSTEM AND IMMUNE-RELATED DISORDERS THROUGH NEURO-IMMUNE MODULATION AND ADVANCED NANO-MEDICINE TECHNOLOGY. THE COMPANY ANNOUNCES THE SUCCESSFUL COMPLETION OF A US$4,500,000 (BEFORE COSTS) CAPITAL RAISE (PLACEMENT) THROUGH THE SUBSCRIPTION OF 5,625,000 UNITS, EACH PRICED AT US$0.80 (~A$1.28).

ARGENT BIOPHARMA LTD. RAISED US$4,500,000

PERTH, AUSTRALIA , JAN. 6, 2025 /PRNEWSWIRE/ --ARGENT BIOPHARMA (ASX: RGT) (OTCQB: RGTLF), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY ADDRESSING UNMET MEDICAL NEEDS BY DEVELOPING INNOVATIVE TREATMENTS FOR CENTRAL NERVOUS SYSTEM AND IMMUNE-RELATED DISORDERS THROUGH NEURO-IMMUNE MODULATION AND ADVANCED NANO-MEDICINE TECHNOLOGY. THE COMPANY ANNOUNCES THE SUCCESSFUL COMPLETION OF A US$4,500,000 (BEFORE COSTS) CAPITAL RAISE (PLACEMENT) THROUGH THE SUBSCRIPTION OF 5,625,000 UNITS, EACH PRICED AT US$0.80 (~A$1.28).

ARGENT BIOPHARMA LTD. PLACING TO RAISE US$4,500,000

NEW YORK , DEC. 2, 2024 /PRNEWSWIRE/ -- ROYCE GLOBAL TRUST, INC. (NYSE-RGT) (THE "FUND") HAS DECLARED A YEAR-END DISTRIBUTION OF $0.47 PER SHARE ON ITS COMMON STOCK. THE DISTRIBUTION, OPTIONALLY PAYABLE IN ADDITIONAL SHARES OF COMMON STOCK, OR IN CASH BY SPECIFIC STOCKHOLDER ELECTION, IS TO BE PAID ON DECEMBER 23, 2024 TO STOCKHOLDERS OF RECORD AT THE CLOSE OF BUSINESS ON DECEMBER 12, 2024 (EX-DIVIDEND ON DECEMBER 12, 2024).

Royce Global Value Trust, Inc.

RGT

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Royce Global Value Trust, Inc.

RGT.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

RGT